Replies to post #431 on Vaxart Inc (VXRT)

[RAND]

The transaction maximizes the value of Aviragen: Based on the valuations of a selected set of publicly traded vaccine companies, Vaxart’s estimated potential valuation prior to the merger is approximately $158 million. Based on the ownership structure in the transaction, this would imply a value of the combined company at $264 million, with the potential value of Aviragen in the merger being $106 million, a significant improvement in value compared to Aviragen’s current market capitalization of approximately $23 million

[DewDiligence]

Shareholder approval is a fait accompli. Anyone who doesn't like the deal terms has already sold or will do so by the time of the shareholder vote in February.